 |
About Chronic Lymphocytic Leukemia (CLL)— RITUXAN® (Rituximab) Website
Information about CLL (chronic lymphocytic leukemia), a type of cancer and the most common chronic leukemia. Learn more about CLL symptoms, CLL treatment, and get useful tips about talking to your doctor. INDICATIONS: RITUXAN (Rituximab) is indicated in combination with fludarabine and cyclophosphamide (FC chemotherapy) for the treatment of patients with: Previously untreated CD20-positive CLL,Previously treated CD20-positive CLL. People with serious infections should not receive RITUXAN. IMPORTANT SAFETY INFORMATION: RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection). RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death. The most common side effects of RITUXAN seen in clinical trials of patients with CLL were infusion reactions and low white blood cells, which can increase the risk of infections. Before starting treatment with RITUXAN it is important for you to talk to your doctor about your medical history. Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor. Please see full Prescribing Information, including Medication Guide, in PDF format.
Rituxancll.com ~
Site Info
Whois
Trace Route
RBL Check
|
 |
Rituxan (Rituximab) for Rheumatoid Arthritis and Non-Hodgkins Lymphoma
Rituxan (Rituximab) is a unique therapy that works by selectively depleting CD20+ B-cells. B-cells, and their role in cancer and autoimmune diseases, have been an area of intensive research by scientists around the world, and at Genentech and Biogen Idec. Rituxan affects your immune system by selectively targeting CD20+ B-cells shown to play an important role in non-Hodgkin's lymphoma and rheumatoid arthritis.
Rituxan.com ~
Site Info
Whois
Trace Route
RBL Check
|
|
|
|
Site Info
